Tag: M.W=300-400

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 41575-94-4, is researched, Molecular C6H12N2O4Pt, about Prospective feasibility study of neoadjuvant dose-dense paclitaxel plus carboplatin with bevacizumab therapy followed by interval debulking surgery for advanced ovarian, fallopian tube, and primary peritoneal cancer patients, the main research direction is ovarian fallopian tube primary peritoneal cancer paclitaxel carboplatin; bevacizumab neoadjuvant chemotherapy dose interval debulking surgery; Bevacizumab; Dose-dense TC; Feasibility; Neoadjuvant chemotherapy; Ovarian cancer.Related Products of 41575-94-4.

Abstract: Background: This study aimed to investigate the clin. benefit of dose-dense paclitaxel plus carboplatin (TC) with bevacizumab therapy for advanced ovarian, fallopian tube, and primary peritoneal cancer patients in the neoadjuvant setting. Methods: Ovarian, fallopian tube or primary peritoneal cancer patients with stage III-IV disease received neoadjuvant chemotherapy (NAC) every 3 wk consisting of paclitaxel (80 mg/m2) on days 1, 8, and 15; carboplatin (AUC 6.0 mg/mL x min.) on day 1; and bevacizumab (15 mg/kg) on day 1. Interval debulking surgery (IDS) was performed after 3 cycles of dose-dense TC-bevacizumab therapy. The primary endpoint was the rate of complete resection by IDS. Secondary endpoints were treatment completion rate, treatment exposure, response rate to NAC, adverse events, and perioperative complications. Results: Twenty-four patients were included in this study. The median age was 55.5 years (37-80 years), and most patients had high-grade serous carcinoma accounted (n = 18). IDS was performed in all patients with complete resection achieved in 75‰ (95‰ confidence interval: 57.7-92.3‰). The lower limit exceeded the preset threshold rate of 55‰. The response rate to NAC was 79‰, and serum CA125 levels were in the normal range after NAC in 57‰ of patients. Grade 4 hematol. toxicities and grade 3/4 non-hematol. toxicities occurred in 29‰ and 17‰ of patients during NAC, resp. Grade 3/4 perioperative complications were seen in 29‰ of patients, but no gastrointestinal perforations or treatment-related deaths occurred. Conclusions: Neoadjuvant dose-dense TC-bevacizumab therapy was well tolerated, and a satisfactory rate of complete resection by IDS was achieved.

In some applications, this compound(41575-94-4)Related Products of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《Partial response of metastatic cardia neuroendocrine carcinoma with the combined therapy involving PD-1 blockade after failed multi-line chemotherapies: a case report and literature review》. Authors are Yang, Yang; Xu, Huan; Zhang, Li; Bai, Liangliang; Zhu, Hong; Li, Qiu.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).Category: esters-buliding-blocks. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

Cardia neuroendocrine cancer is a rare malignant tumor. The treatment regimens mainly refer to the small-cell lung cancer diagnosis and treatment guidelines and there is no standard treatment guideline specifically for neuroendocrine cancer. The use of albumin paclitaxel plus carboplatin combined with sintilimab for refractory cardia neuroendocrine carcinoma (NEC) has never been reported. This article reported a case that a 68-yr-old man presented with belching without obvious reasons who was diagnosed with refractory cardia NEC by gastroscopy and pathol. results. After failure of multi-line therapy including etoposide plus cisplatin as the first-line therapy, surufatinib plus toripalimab as the second-line therapy, FOLFIRI combined with bevacizumab as the third-line therapy, he received three cycles of albumin paclitaxel plus carboplatin combined with sintilimab as the fourth-line therapy and still obtained partial response of good efficiency. After the patient received this treatment regimen, the symptoms of dysphagia disappeared and the change trends of neuron-specific enolase were decreased. The computed tomog. (CT) examination after three cycles of treatment was performed to show that the measured lesions have shrunk by more than 30% compared to the baseline CT. Addnl., there were no other adverse events such as nausea, vomiting, and diarrhea, except for grade III bone marrow suppression. At present, the patient is still being treated. This is the first case report that the albumin paclitaxel plus carboplatin combined with sintilimab has achieved good efficacy after failure of multi-line treatment of cardia NEC. It is very necessary to further explore the effectiveness and safety of this regimen in the treatment of NEC.

In some applications, this compound(41575-94-4)Category: esters-buliding-blocks is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Application of 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about The clinical utility of next-generation sequencing for bone and soft tissue sarcoma. Author is Gusho, Charles A.; Weiss, Mia C.; Lee, Linus; Gitelis, Steven; Blank, Alan T.; Wang, Dian; Batus, Marta.

Sarcomas are a rare and heterogeneous tumor group composed of a variety of histol. subtypes. Targeted next-generation sequencing (NGS) of bone and soft tissue sarcomas is a nascent field with limited evidence for its use within clin. practice. Therefore, further research is needed to validate NGS in sarcoma and assess the clin. utility of these techniques with the hope of improving treatment options. Comprehensive mol. profiling with NGS was performed on 136 tumors (116 soft tissue, 20 bone) using two com. vendors. Patient records were retrospectively reviewed, and the clin. impact of NGS-related findings were qual. analyzed to determine actionable mutations and number of changes in treatment. The median age was 55.0 years (IQR 42-67 years), and most patients were non-metastatic at presentation (80.9%, n = 110). Prior to performing NGS, 72.1% (n = 98) were treated with a mean 1.1 ± 1.2 lines of systemic chemotherapy. NGS identified 341 putative alterations with at least one mutation present in 89.7% (n = 122) of samples. In a subset of 111 patients with available TMB data, 78.7% (n = 107) had a low (<6 m/Mb) mutational burden. Among all 136 cases, 47.1% (n = 64) contained clin. actionable alterations, and 12 patients had a change in medical treatment based on NGS. Those who underwent a treatment change all had metastatic or recurrent disease; three of these patients experienced a clin. benefit. Most bone and soft tissue sarcomas harbor at least one genetic alteration, and it appears a sizeable number of tumors contain mutations that are clin. actionable. While a change in treatment based off NGS-related findings occurred in 12 cases, three patients experienced a clin. benefit. Our data provide further proof-of-concept for NGS in sarcoma and suggest a clin. benefit may be observed in select patients. In some applications, this compound(41575-94-4)Application of 41575-94-4 is unique.If you want to know more details about this compound, you can contact with the author or consult more relevant literature.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Recommanded Product: 41575-94-4. The fused heterocycle is formed by combining a benzene ring with a single heterocycle, or two or more single heterocycles. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Cost-effectiveness analysis of pembrolizumab for treatment of US patients with persistent, recurrent, or metastatic cervical cancer.. Author is Shi, Yang; Chen, Jigang; Shi, Bo; Liu, Aihua.

OBJECTIVE: The effectiveness of pembrolizumab for persistent, recurrent, or metastatic cervical cancer has been demonstrated. We aimed to evaluate its cost-effectiveness from the United States (US) healthcare payers perspective. METHODS: A partitioned survival model over a 30-year lifetime horizon was developed to compare the cost and effectiveness of pembrolizumab versus placebo based on clinical data from the KEYNOTE-826 phase 3 randomized trial. Costs and health state utilities were obtained from literature and publicly available databases. The incremental cost-effectiveness ratio (ICER) was measured. One-way and probabilistic sensitivity analyses were conducted. RESULTS: For the Intention-to-Treat patients, pembrolizumab was associated with an additional 0.74 quality-adjusted life-year (QALY) at an additional cost of $182,271 when compared with placebo. The ICER was $247,663/QALY. For patients with a programmed death-ligand 1 combined positive score ≥ 1 and 10, the ICER was $253,322/QALY and $214,212/QALY, respectively. One-way sensitivity analyses showed that pembrolizumab had the greatest impact on the ICER. Probabilistic sensitivity analyses showed that the probability of pembrolizumab being cost-effective was zero at the current willingness-to-pay threshold of $150,000/QALY. The price of pembrolizumab had to reduce at least to $28.336 (55.8% of the current price) for it to be cost-effective in a 50% of chance. CONCLUSION: The addition of pembrolizumab to chemotherapy is costly and might not be cost-effective for persistent, recurrent, or metastatic cervical cancer at the current price in the US.

This literature about this compound(41575-94-4)Recommanded Product: 41575-94-4has given us a lot of inspiration, and I hope that the research on this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)) can be further advanced. Maybe we can get more compounds in a similar way.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

HPLC of Formula: 41575-94-4. The mechanism of aromatic electrophilic substitution of aromatic heterocycles is consistent with that of benzene. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about Vinblastine monotherapy induction prior to radiotherapy for patients with intracranial germinoma during the COVID-19 pandemic. Author is Murray, Matthew J.; Moleron, Rafael; Adamski, Jennifer; English, Martin; Burke, G. A. Amos; Cross, Justin; Ajithkumar, Thankamma; Stoneham, Sara; Nicholson, James C..

Patients with localized intracranial germinoma have excellent survival. Reducing treatment burden and long-term sequelae is a priority. Intensive inpatient chemotherapy (e.g., carbo PEI = carboplatin/etoposide/ifosfamide) has been effectively employed to reduce radiotherapy treatment volume/dose. Outpatient-based carboplatin monotherapy is associated with excellent outcomes in metastatic testicular seminoma (an identical pathol.), and successful vinblastine monotherapy induction (with 77% tumor volume reduction after just two weekly vinblastine doses) has recently been reported in an intracranial germinoma patient. Adapted UK guidelines for germ cell tumor management were distributed during the COVID-19 pandemic, including nonstandard treatment options to reduce hospital visits and/or admissions. This included vinblastine monotherapy for intracranial germinoma (6 mg/m2 i.v., or 4 mg/m2 for moderate count suppression, delivered weekly). We describe two such patients treated using this approach. A 30-yr-old male with a localized pineal tumor received 12-wk vinblastine induction, with >60% volume reduction, prior to definitive radiotherapy. A 12-yr-old female with a metastatic suprasellar tumor and progression at all sites of disease while awaiting proton radiotherapy received two vinblastine doses with good early response, including 36% primary tumor volume reduction The patients tolerated vinblastine well. Patients with intracranial germinoma have excellent outcomes, and reduction of late effects remains a priority. The description of vinblastine monotherapy in these intracranial germinoma patients warrants further exploration.

As far as I know, this compound(41575-94-4)HPLC of Formula: 41575-94-4 can be applied in many ways, which is helpful for the development of experiments. Therefore many people are doing relevant researches.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Computed Properties of C6H12N2O4Pt. Aromatic heterocyclic compounds can also be classified according to the number of heteroatoms contained in the heterocycle: single heteroatom, two heteroatoms, three heteroatoms and four heteroatoms. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), is researched, Molecular C6H12N2O4Pt, CAS is 41575-94-4, about FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.. Author is Debieuvre, Didier; Dayen, Charles; Dixmier, Adrien; Pau, David; Sibley-Revelat, Anna; Greenwood, William; Gally, Samuel; Falchero, Lionel.

OBJECTIVES: FRESC reanalyzed extensive-stage small-cell lung cancer (ES-SCLC) patient data from the French KBP-2010 cohort to describe the characteristics and therapeutic management of ES-SCLC and provide real-world estimates of survival. METHODS: A target population of first line (1L) ES-SCLC was identified at initial diagnosis in KBP-2010 (KBP population, N = 796). A KBP-2010 subpopulation was defined as patients who also met the IMpower133 clinicaltrial PS ≤ 1 inclusion criteria (KBP-PS_0/1 population, N = 394). Subgroups were defined according to the 1L ES-SCLC chemotherapy regimens: carboplatin or cisplatin with etoposide (Carb-E or Cisp-E subgroups). RESULTS: The vast majority of KBP populations exhibited stage IV ES-SCLC (84.9%) at initial diagnosis. Median age was 66 years; patients were mostly male and smokers. Patients receiving Cisp + Eto were younger (median age 61 years [55.0-67.0]) and fitter (25.5% had PS ≥ 2) than those receiving Carb + Eto (71 years [62.5-77.5]; 44.1%had PS ≥ 2). Median overall survival (OS) of chemotherapy-treated 1L ES-SCLC patients varied from 7.0 months [95% CI, 6.1; 7.8] in the KBPCarb-Esubgroups to 9.6 months [95% CI, 8.4;10.8] in the KBP Cisp-E subgroup. KBP-PS_0/1 population showed better median OS, especially for the Cisp-E subgroup (10 months [95% CI, 8.7; 11.3]). CONCLUSION: In the KBP-PS_0/1 population, median OS was close to the one that was found in the IMpower133 control arm. Although this needs to be confirmed by further research, it suggests the transposability of the IMpower133 results to real-life conditions.

From this literature《FRESC: French Real world Extensive stage SCLC Cohorts: A retrospective study on patient characteristics and treatment strategy based on KBP-2010.》,we know some information about this compound(41575-94-4)Computed Properties of C6H12N2O4Pt, but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The reaction of an aromatic heterocycle with a proton is called a protonation. One of articles about this theory is 《A 33-Year-Old Man With Chest Pain.》. Authors are Ballenberger, Matthew; Vojnic, Morana; Indaram, Madhuri; Machnicki, Stephen; Harshan, Manju; Novoselac, Amory V; Singh, Anup; Mina, Bushra.The article about the compound:cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)cas:41575-94-4,SMILESS:O=C1C2(CCC2)C(O[Pt]O1)=O.N.N).HPLC of Formula: 41575-94-4. Through the article, more information about this compound (cas:41575-94-4) is conveyed.

CASE PRESENTATION: A 33-year-old man was admitted with a 4-week history of intermittent, right-sided chest pain. Two weeks before the incident, he had completed a 10-day course of levofloxacin for a presumed right-sided pneumonia without much improvement. He denied any dyspnea, cough, sputum production, hemoptysis, night sweats, or weight loss. He was an active smoker with a 20-pack-year smoking history and 1-year history of vaping nicotine.

From this literature《A 33-Year-Old Man With Chest Pain.》,we know some information about this compound(41575-94-4)HPLC of Formula: 41575-94-4, but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Most of the natural products isolated at present are heterocyclic compounds, so heterocyclic compounds occupy an important position in the research of organic chemistry. A compound: 41575-94-4, is researched, SMILESS is O=C1C2(CCC2)C(O[Pt]O1)=O.N.N, Molecular C6H12N2O4PtJournal, Clinical Trial, Phase II, Article, Randomized Controlled Trial, Breast Cancer Research and Treatment called Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up, Author is Zheng, Fangchao; Du, Feng; Wang, Wenmiao; Wang, Yongsheng; Li, Ming; Zhao, Jiuda; Wang, Xue; Yue, Jian; Wang, Jiayu; Yang, Zixuan; Cai, Ruigang; Ma, Fei; Fan, Ying; Li, Qing; Zhang, Pin; Xu, Binghe; Yuan, Peng, the main research direction is BRCA; ECT regimen; SPARC; TP regimen; Triple-negative breast cancer.Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II).

Abstract: Background: Paclitaxel/docetaxel after doxorubicin plus cyclophosphamide (ECT) is considered as an adjuvant chemotherapy and improves the survival of early triple-neg. breast cancer (TNBC) patients. We aim to assess whether carboplatin plus taxanes (TP) is non-inferior to ECT in prolonging the survival time. Methods: TNBC patients were randomized (1:1) to receive ECT (90 mg/m2 epirubicin + 600 mg/m2 cyclophosphamide followed by 75 mg/m2 docetaxel or 175 mg/m2 paclitaxel every 3 wk, n = 154) or TP (75 mg/m2 docetaxel or 175 mg/m2 paclitaxel + carboplatin AUC 5 every 3 wk, n = 154). These expression of SPARC, PD-L1, and BRCA were studied. Patients were followed up for disease-free survival (DFS), overall survival (OS), and safety. Results: We recruited 308 TNBC patients (median follow-up of 97.6 mo). The median DFS and OS were not reached; the 8-yr DFS rate of ECT and TP arms was 78.4% and 81.7%, resp., while the 8-yr OS rate were 87.2% and 89.1%, resp. In the SPARC (> 50%) subgroup anal., the TP arm had longer DFS (P = 0.049) and a tendency with better OS (P = 0.06) than ECT arm. No significant differences were observed in the DFS and OS between the ECT arm and TP arm in TNBC with SPARC (≤ 50%), PD-L1 (-) PD-L1 (+), and BRCA mutation or BRCA wild (all P values > 0.05). Conclusion: TP showed non-inferiority for DFS and OS compared with ECT in early TNBC. TP may be an effective alternative chemotherapy for TNBC patients whom the standard ECT regimen is not being used. Trail Registration: ClinicalTrials.gov identifier NCT01150513

From this literature《Updated efficacy of adjuvant epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes in early triple-negative breast cancer in phase 2 trial: 8.1-year median follow-up》,we know some information about this compound(41575-94-4)Reference of cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II), but this is not all information, there are many literatures related to this compound(41575-94-4).

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

The preparation of ester heterocycles mostly uses heteroatoms as nucleophilic sites, which are achieved by intramolecular substitution or addition reactions. Compound: cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)( cas:41575-94-4 ) is researched.Electric Literature of C6H12N2O4Pt.Zhang, Liulu; Wu, Zhi-Yong; Li, Jie; Lin, Ying; Liu, Zhenzhen; Cao, Yin; Zhang, Gangling; Gao, Hong-Fei; Yang, Mei; Yang, Ci-Qiu; Zhu, Teng; Cheng, Min-Yi; Ji, Fei; Li, Jieqing; Wang, Kun published the article 《Neoadjuvant docetaxel plus carboplatin vs epirubicin plus cyclophosphamide followed by docetaxel in triple-negative , early-stage breast cancer ( NeoCART ): Results from a multicenter, randomized controlled, open-label phase II trial》 about this compound( cas:41575-94-4 ) in International Journal of Cancer. Keywords: docetaxel carboplatin epirubicin cyclophosphamide triple neg breast cancer; phase II trial; carboplatin; neoadjuvant chemotherapy; triple-negative breast cancer. Let’s learn more about this compound (cas:41575-94-4).

Previous studies have shown that the addition of carboplatin to neoadjuvant chemotherapy improved the pathol. complete response (pCR) rate in patients suffering from triple-neg. breast cancer (TNBC) and patients who obtained a pCR could achieve prolonged event-free survival (EFS) and overall survival (OS). However, no studies have assessed the effects of the combination of docetaxel and carboplatin without anthracycline with taxane-based and anthracycline-based regimens. The NeoCART study was designed as a multicenter, randomized controlled, open-label, phase II trial to assess the efficacy and safety of docetaxel combined with carboplatin in untreated stage II-III TNBC. All eligible patients were randomly assigned, at a 1:1 ratio, to an exptl. docetaxel plus carboplatin (DCb) for six cycles group (DCb group) or an epirubicin plus cyclophosphamide for four cycles followed by docetaxel for four cycles group (EC-D group). PCR (ypT0/is ypN0) was evaluated as the primary outcome. Between 1 Sept. 2016 and 31 Dec. 2019, 93 patients were randomly assigned and 88 patients were evaluated for the primary endpoint (44 patients in each group). In the primary endpoint anal., 27 patients in the DCb group (61.4%, 95% CI 47.0-75.8) and 17 patients in the EC-D group achieved a pCR (38.6%, 95% CI 24.3-53.0; odds ratio 2.52, 95% CI 2.4-43.1; Pnoninferiority = .004). Noninferiority was met, and the DCb regimen was confirmed to be superior to the EC-D regimen (P = .044, superiority margin of 5%). At the end of the 37-mo median follow-up period, OS and EFS rates were equivalent in both groups.

Compound(41575-94-4)Electric Literature of C6H12N2O4Pt received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(cis-Diammine(1,1-cyclobutanedicarboxylato)platinum(II)), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics

Epoxy compounds usually have stronger nucleophilic ability, because the alkyl group on the oxygen atom makes the bond angle smaller, which makes the lone pair of electrons react more dissimilarly with the electron-deficient system. Compound: 2-Chloro-3,4-diiodopyridine, is researched, Molecular C5H2ClI2N, CAS is 153034-91-4, about First metalation of aryl iodides: directed ortho-lithiation of iodopyridines, halogen-dance, and application to synthesis.Safety of 2-Chloro-3,4-diiodopyridine.

Metalation of iodopyridines was successfully achieved by LDA at low temperature In many cases, lithiation is ortho directed by the iodo group which subsequently ortho-migrates very fast to give stabilized iodolithiopyridines. This procedure was applied to 2-fluoro- and 2-chloro-3-iodopyridines, 3-fluoro-4-iodopyridine, and 2-chloro-3-fluoro-4-iodopyridine. The resulting lithio intermediates were obtained in high yields before being reacted with electrophiles leading to various polysubstituted pyridines. Some of these iodopyridines were used as key mols. for the preparation of fused polyaromatic alkaloids. Thus, perlolidine (I), δ-carbolines, and 2,10-diazaphenanthrenes were readily prepared in few steps taking advantage of the iodo reactivity for heteroring cross-coupling. Coupling of [2-(pivaloylamino)phenyl]boronic acid with 2-fluoro-4-iodo-3-pyridinecarboxaldehyde gave I.

Compound(153034-91-4)Safety of 2-Chloro-3,4-diiodopyridine received a lot of attention, and I have introduced some compounds in other articles, similar to this compound(2-Chloro-3,4-diiodopyridine), if you are interested, you can check out my other related articles.

Reference:
Ester – Wikipedia,
Ester – an overview | ScienceDirect Topics